Lower Cretaceous (Hauterivian-Albian) ammonite biostratigraphy in the Maestrat Basin (E Spain)

Peer reviewedPublisher PD

Lower Cretaceous (Hauterivian-Albian) ammonite biostratigraphy in the Maestrat Basin (E Spain)

A review of the stratigraphic distribution of ammonoid species in the Lower Cretaceous (Hauterivian-Albian) of the Maestrat Basin (E Spain) was carried out. The specimens were mainly collected in the field by us and are stored in university or museum collections. Speci­mens from private collections and figured in the literature were also studied. We recognized 73 species that are distributed, in accordance with the latest version of the standard Mediterranean ammonite zonation for the Lower Cretaceous, in 14 ammonite zones: Acanthodiscus radiatus, Crioceratites loryi, Lyticoceras nodosoplicatum (Lower Hauterivian); Pseudothurmannia ohmi (Upper Hauterivian); Imerites giraudi (Upper Barremian); Deshayesites oglanlensis, Deshayesites forbesi, Deshayesites deshayesi, Dufrenoyia furcata (Lower Aptian); Epicheloniceras martini, Parahoplites melchioris, Acanthohoplites nolani (Upper Aptian); Leymeriella tardefurcata and Douvilleiceras mammillatum (Lower Albian). The recognition of these biozones allows a precise age calibration of the Maestrat Basin’s lithostatigraphic units that contain ammonoids as well as an associated indirect age calibration of the formations without ammonoids. Consequently, this report provides an updated, comprehensive and precise biostratigraphic framework, which aims to become a reference for the analysis of the Lower Cretaceous strata of the Maestrat Basin. The results are also relevant for the analysis of coeval ammonite-bearing sedimentary successions found in other Tethyan basins.En este trabajo se ha realizado una revisión detallada de la distribución estratigráfica de las especies de ammonoideos del Cretácico infe­rior de la Cuenca del Maestrazgo (Este de España). Los ejemplares recolectados, principalmente por los autores, han sido depositados en co­lecciones universitarias y museísticas. Además hemos estudiado los ejemplares de colecciones privadas y figurados en la literatura. Hemos reconocido 73 especies que se distribuyen, siguiendo la última versión de la biozonación de ammonites mediterránea estándar del Cretácico inferior, en 14 zonas de ammonoideos: Acanthodiscus radiatus, Crioceratites loryi, Lyticoceras nodosoplicatum (Hauteriviense inferior); Pseudothurmannia ohmi (Hauteriviense superior); Imerites giraudi (Barremiense superior); Deshayesites oglanlensis, Deshayesites forbesi, Deshayesites deshayesi, Dufrenoyia furcata (Aptiense inferior); Epicheloniceras martini, Parahoplites melchioris, Acanthohoplites nolani (Aptiense superior); Leymeriella tardefurcata y Douvilleiceras mammillatum (Albiense inferior). El reconocimiento de estas biozonas permite precisar la edad de las unidades litoestratigráficas que contienen ammonites y también una calibración indirecta de las formaciones que no contienen ammonites. En consecuencia este trabajo proporciona un marco bioestratigráfico actualizado, exhaustivo y preciso que pretende ser una referencia para el análisis estratigráfico del Cretácico inferior de la Cuenca del Maestrazgo. Los resultados obtenidos son también relevantes para el análisis de las sucesiones sedimentarias coetáneas con ammonites existentes en otras cuencas de Tetis

The Current State of Performance Appraisal Research and Practice: Concerns, Directions, and Implications

On the surface, it is not readily apparent how some performance appraisal research issues inform performance appraisal practice. Because performance appraisal is an applied topic, it is useful to periodically consider the current state of performance research and its relation to performance appraisal practice. This review examines the performance appraisal literature published in both academic and practitioner outlets between 1985 and 1990, briefly discusses the current state of performance appraisal practice, highlights the juxtaposition of research and practice, and suggests directions for further research

The role of mergers in driving morphological transformation over cosmic time

Accepted for publication in MNRASUnderstanding the processes that trigger morphological transformation is central to understanding how and why the Universe transitions from being disc-dominated at early epochs to having the morphological mix that is observed today. We use Horizon-AGN, a cosmological hydrodynamical simulation, to perform a comprehensive study of the processes that drive morphological change in massive (M*/M ⊙ > 10 10) galaxies over cosmic time. We show that (1) essentially all the morphological evolution in galaxies that are spheroids at z = 0 is driven by mergers with mass ratios greater than 1: 10; (2) major mergers alone cannot produce today's spheroid population - minor mergers are responsible for a third of all morphological transformation over cosmic time and are its dominant driver after z ~ 1; (3) prograde mergers trigger milder morphological transformation than retrograde mergers - while both types of event produce similar morphological changes at z > 2, the average change due to retrograde mergers is around twice that due to their prograde counterparts at z ~ 0; (4) remnant morphology depends strongly on the gas fraction of a merger, with gas-rich mergers routinely re-growing discs; and (5) at a given stellar mass, discs do not exhibit drastically different merger histories from spheroids - disc survival in mergers is driven by acquisition of cold gas (via cosmological accretion and gas-rich interactions) and a preponderance of prograde mergers in their merger histories.Peer reviewedFinal Accepted Versio

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population

BackgroundThe objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting.MethodsA Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared with docetaxel. Costs were collected from the Spanish healthcare perspective.ResultsOutcomes of the model included total costs, total quality-adjusted life years (QALYs), total life years gained (LYG) and total progression-free survival (PFS). Mean survival was 1.03 years for the pemetrexed arm and 0.89 years in the docetaxel arm; QALYs were 0.52 compared to 0.42. Per-patient lifetime costs were € 34677 and € 32343, respectively. Incremental cost-effectiveness ratios were € 23967 per QALY gained and € 17225 per LYG.ConclusionsPemetrexed as a second-line treatment option for patients with a predominantly non-squamous histology in NSCLC is a cost-effective alternative to docetaxel according to the € 30000/QALY threshold commonly accepted in Spain

The Dramatic Size and Kinematic Evolution of Massive Early-type Galaxies

We aim to provide a holistic view on the typical size and kinematic evolution of massive early-type galaxies (ETGs) that encompasses their high-z star-forming progenitors, their high-z quiescent counterparts, and their configurations in the local Universe. Our investigation covers the main processes playing a relevant role in the cosmic evolution of ETGs. Specifically, their early fast evolution comprises biased collapse of the low angular momentum gaseous baryons located in the inner regions of the host dark matter halo; cooling, fragmentation, and infall of the gas down to the radius set by the centrifugal barrier; further rapid compaction via clump/gas migration toward the galaxy center, where strong heavily dust-enshrouded star formation takes place and most of the stellar mass is accumulated; and ejection of substantial gas amount from the inner regions by feedback processes, which causes a dramatic puffing-up of the stellar component. In the late slow evolution, passive aging of stellar populations and mass additions by dry merger events occur. We describe these processes relying on prescriptions inspired by basic physical arguments and by numerical simulations to derive new analytical estimates of the relevant sizes, timescales, and kinematic properties for individual galaxies along their evolution. Then we obtain quantitative results as a function of galaxy mass and redshift, and compare them to recent observational constraints on half-light size Re, on the ratio v/\u3c3 between rotation velocity and velocity dispersion (for gas and stars) and on the specific angular momentum j 17of the stellar component; we find good consistency with the available multiband data in average values and dispersion, both for local ETGs and for their z 3c 1-2 star-forming and quiescent progenitors. The outcomes of our analysis can provide hints to gauge sub-grid recipes implemented in simulations, to tune numerical experiments focused on specific processes, and to plan future multiband, high-resolution observations on high-redshift star-forming and quiescent galaxies with next-generation facilities

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non–Small Cell Lung Carcinoma: the ROSING Study

Introduction: The ROS1 gene rearrangement has become an important biomarker in NSCLC. The College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology testing guidelines support the use of ROS1 immunohistochemistry (IHC) as a screening test, followed by confirmation with fluorescence in situ hybridization (FISH) or a molecular test in all positive results. We have evaluated a novel anti-ROS1 IHC antibody (SP384) in a large multicenter series to obtain real-world data. Methods: A total of 43 ROS1 FISH-positive and 193 ROS1 FISH-negative NSCLC samples were studied. All specimens were screened by using two antibodies (clone D4D6 from Cell Signaling Technology and clone SP384 from Ventana Medical Systems), and the different interpretation criteria were compared with break-apart FISH (Vysis). FISH-positive samples were also analyzed with next-generation sequencing (Oncomine Dx Target Test Panel, Thermo Fisher Scientific). Results: An H-score of 150 or higher or the presence of at least 70% of tumor cells with an intensity of staining of 2+ or higher by the SP384 clone was the optimal cutoff value (both with 93% sensitivity and 100% specificity). The D4D6 clone showed similar results, with an H-score of at least 100 (91% sensitivity and 100% specificity). ROS1 expression in normal lung was more frequent with use of the SP384 clone (p < 0.0001). The ezrin gene (EZR)-ROS1 variant was associated with membranous staining and an isolated green signal FISH pattern (p = 0.001 and p = 0.017, respectively). Conclusions: The new SP384 ROS1 IHC clone showed excellent sensitivity without compromising specificity, so it is another excellent analytical option for the proposed testing algorithm

Caracterización de la púrpura trombótica trombocitopénica congénita mediante técnicas inmunológicas y moleculares: resultados de la colección nacional del GEPTT

CO-093 Introducción: La Púrpura Trombótica Trombocitopénica congénita (PTTc) es una enfermedad ultra-rara caracterizada por un déficit severo de la enzima ADAMTS13 como consecuencia de mutaciones heredadas de forma autosómica recesiva en el gen ADAMTS13 (9q34). En este estudio, desarrollado dentro del Grupo Cooperativo Español de PTT (GEPTT), se ha llevado a cabo la creación de una colección centralizada de muestras biológicas y su caracterización inmunológica y molecular para mejorar el diagnóstico y el manejo clínico de los pacientes. Métodos: Se incluyeron en este estudio seis pacientes con diagnóstico clínico o sospecha de PTTc de diferentes hospitales españoles. Se estudió la actividad de ADAMTS13 e inhibidores mediante la técnica ELISA con el kit “TECHNOZYM® ADAMTS-13 Activity e INH” (Technoclone). Además, se realizó test Bethesda para descartar la presencia de inhibidores no IgG. Para el estudio genético, se implementó un panel de captura (SureSelect, Agilent) dirigido a la región genómica completa, incluyendo también las regiones no codificantes, del gen ADAMTS13 (chr9: 136278459 - 136325025, hg19). Las librerías de DNA se secuenciaron con la plataforma MiSeq (Illumina®) y el posible efecto patogénico de las variantes identificadas se estudió a nivel de i) proteína, utilizando predictores de cambio de aminoácido (SIFT) y de estructura de la proteína (SwissModel) y ii) splicing, con herramientas de análisis in silico (HSF) y validación funcional in vitro mediante minigenes. En 3 casos se realizó un cariotipo molecular utilizando array de SNPs (CytoScan HD, Affymetrix) para detectar regiones de pérdida de material genético y/o de heterocigosidad (LOH). Resultados: La mediana de actividad de ..